Ballentine Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ballentine Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$289K	Sell	1,827 -112	-6%	-$15.1K	﹤0.01%	810
2026 Q1	$248K	Buy	1,939 +112	+6%	+$14K	﹤0.01%	827
2025 Q4	$223K	Buy	+1,827	New	+$209K	﹤0.01%	878
2025 Q3	–	Sell	-17,771	Closed	-$1.47M	–	1070
2025 Q2	$1.47M	Hold	17,771	–	–	0.02%	249
2025 Q1	$1.44M	Buy	+17,771	New	+$1.59M	0.03%	233
2024 Q2	–	Sell	-27,066	Closed	-$2.57M	–	809
2024 Q1	$2.57M	Hold	27,066	–	–	0.05%	128
2023 Q4	$2.42M	Hold	27,066	–	–	0.05%	126
2023 Q3	$1.98M	Sell	27,066 -283	-1%	-$22.6K	0.05%	125
2023 Q2	$2.28M	Sell	27,349 -23,231	-46%	-$1.94M	0.05%	112
2023 Q1	$3.85M	Buy	50,580 +9,700	+24%	+$805K	0.1%	82
2022 Q4	$3.39M	Buy	40,880 +1,097	+3%	+$88.8K	0.1%	76
2022 Q3	$3.16M	Hold	39,783	–	–	0.11%	70
2022 Q2	$2.96M	Buy	+39,783	New	+$2.99M	0.1%	73
2017 Q4	–	Sell	-1,496	Closed	-$130K	–	429
2017 Q3	$130K	Hold	1,496	–	–	0.01%	373
2017 Q2	$121K	Buy	+1,496	New	+$106K	0.01%	373

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Parkside Investments Deerfield, Illinois $902M AUM 32.45% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

MAM

Marotta Asset Management Charlottesville, Virginia $601M AUM 21.35% 1-Year Est. Return

Ballentine Partners's XBI Position: Q2 2026 in Review

Ballentine Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5.8% in Q2 2026, selling an estimated $15.1K and leaving 1,827 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #810.

Ballentine Partners first reported a position in XBI in Q2 2017 and has held it in 15 quarters since. The position peaked at $3.85M in Q1 2023. 131 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Ballentine Partners held 1,827 shares of State Street SPDR S&P Biotech ETF worth $289K as of Q2 2026.
Ballentine Partners sold 112 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $15.1K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #810 holding.
Ballentine Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 15 quarters since.
Ballentine Partners's State Street SPDR S&P Biotech ETF position peaked at $3.85M in Q1 2023.
131 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.